Guardant Health, Inc. (NASDAQ:GH) Stake Cut by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd lessened its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,561,979 shares of the company's stock after selling 526,215 shares during the quarter. Temasek Holdings Private Ltd owned approximately 1.26% of Guardant Health worth $47,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares during the last quarter. Deep Track Capital LP raised its stake in Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock valued at $196,118,000 after purchasing an additional 419,006 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares in the last quarter. Nikko Asset Management Americas Inc. raised its position in Guardant Health by 15.6% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 197,729 shares in the last quarter. Finally, Norges Bank acquired a new stake in Guardant Health during the 4th quarter valued at $36,438,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Stock Down 7.2%

Shares of NASDAQ:GH traded down $2.88 on Wednesday, reaching $37.09. The company had a trading volume of 2,182,867 shares, compared to its average volume of 2,170,414. The stock has a 50-day moving average price of $43.62 and a 200 day moving average price of $39.87. The stock has a market capitalization of $4.60 billion, a P/E ratio of -10.42 and a beta of 1.49. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. During the same period in the prior year, the firm earned ($0.46) EPS. The business's revenue was up 20.8% on a year-over-year basis. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. The trade was a 4.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 107,248 shares of company stock worth $5,254,000. 6.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GH has been the topic of a number of analyst reports. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Barclays lifted their target price on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, May 1st. Mizuho assumed coverage on shares of Guardant Health in a research note on Thursday, April 10th. They set an "outperform" rating and a $55.00 target price for the company. Finally, Raymond James restated an "outperform" rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $52.32.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.